A Multi-center, Randomized, Double-blind, Parallel, Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Fugan Ointment (ZL-3101) in Subjects With Subacute Eczema
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2018
At a glance
- Drugs ZL 3101 (Primary)
- Indications Eczema
- Focus Therapeutic Use
- Sponsors ZAI Lab
- 24 Aug 2018 Primary endpoint has not been met. (Eczema Area and Severity Index (EASI) score changes from baseline to day 21), according to a ZAI Lab media release.
- 24 Aug 2018 According to a ZAI Lab media release, based on the top-line results of this study, the company has decided to discontinue the development of ZL-3101 (Fugan) for the treatment of atopic dermatitis (AD). The study showed that drug was safe and well-tolerated, however, the treatment showed no efficacy differences between placebo and ZL-3101 .
- 25 May 2018 According to a Zai Lab media release, topline results from this study are expected in the second half of 2018.